STAT3 and non-small cell lung carcinoma: According to Mukherjee et al.’s study, in NSCLC with constitutive IL6–STAT3 activation for uncontrolled cell proliferation, targeted blockade of NF-κB and IL-6–STAT3 signaling by quercetin (66 μM of quercetin for 12, 18, 24, 36, and 48 h) represents an innovative approach for treating NSCLC.